Adial Pharmaceuticals
ADIL
9 hedge funds and large institutions have $1.02M invested in Adial Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 5 closing their positions.
1.96% less ownership
Funds ownership: 7.92% → 5.96% (-2%)
31% less funds holding
Funds holding: 13 → 9 (-4)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
99% less capital inflows, than outflows
Capital inflows: $4.48K | Capital outflows: $657K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.48K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$201K |
| 2 |
Raffa Wealth Management
Washington,
District of Columbia
|
-$144K |
| 3 |
Jane Street
New York
|
-$105K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$91K |
| 5 |
Two Sigma Investments
New York
|
-$87K |
ADIL Hedge Fund Activity: Q2 2019 in Review
9 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q2 2019, worth a combined $1.02M — down 63% from $2.75M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ADIL and 1 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 0 added.
The largest buyer was Deutsche Bank, opening a new position worth an estimated $4.48K. The largest seller was Millennium Management, exiting entirely with an estimated $201K sold.
- 9 institutional investors held Adial Pharmaceuticals (ADIL) as of Q2 2019, down from 13 in Q1 2019.
- Funds reported $1.02M of Adial Pharmaceuticals stock for Q2 2019, down 63% quarter-over-quarter.
- 1 fund opened new Adial Pharmaceuticals positions in Q2 2019 and 5 closed out, a net change of -4 holders.
- The largest Adial Pharmaceuticals buyer in Q2 2019 was Deutsche Bank, an estimated $4.48K added.
- The largest Adial Pharmaceuticals seller in Q2 2019 was Millennium Management, an estimated $201K sold.
Based on aggregated 13F filings for Q2 2019.